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Abstract
Acute ventricular septal rupture — ventricular septal defect (VSD) following acute myocardial
infarction remains a critical condition. We present an 80 year-old patient with an acute VSD
following an acute inferior myocardial infarction. Percutaneous VSD closure with an
Amplatzer ventricular septal occluder (AVSO) was performed successfully, two days after
initial admission. In-hospital follow-up was uneventful.
We speculate that percutaneous VSD closure with an AVSO can be an alternative to surgical
correction for these patients. Despite the impressive result, this innovative approach needs
further investigation and refinements before it can be recommended as the treatment of choice
for acute ischemic VSD. (Cardiol J 2007; 14: 411–414)
Key words: myocardial infarction, acute ventricular septal defect, Amplatzer
ventricular septal occluder
Introduction
Despite substantial improvements in surgical
and interventional cardiology techniques for the
treatment of acute myocardial infarction (AMI),
acute ventricular septal rupture — ventricular sep-
tal defect (VSD) remains a challenging clinical con-
dition associated with high mortality and morbidi-
ty. There is acute ischemic insult and loss of the
structural integrity of the interventricular septum
that is, as is very well documented, essential for par-
titioning and providing mechanical support for both
ventricles in the setting of AMI [1]. The interven-
tricular septum also actively participates in the
intracardiac conduction system [2, 3]. The conse-
quences of an acute VSD include right ventricular
failure, atrioventricular block, biventricular failure
and, ultimately, cardiogenic shock. Two types of
acute VSD are presently recognised, namely a sim-
ple direct perforation or a complex multifocal com-
munication with a serpiginous course [4].
The Amplatzer ventricular septal occluder
(AVSO), a self-expandable, self-centring wire-mesh
double disc with a connecting central stent part
(AGA Medical Corporation, Golden Valley, Minne-
sota, USA), has been shown to be effective in the
treatment of congenital VSD, muscular VSD and
some membranous VSD from 4 to 20 mm [5–7]. The
device is now available in sizes of 6–24 mm that are
delivered through 6 to 9 French sheaths [5–7].
Despite its success in congenital VSD, AVSO implan-
tation faces a challenge in acute ischemic VSD in
view of the location of the rupture, the underlying
tissue quality (ischemic and/or necrotic) and, quite
commonly, an already failing right ventricle.
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Case description
We present an 80 year-old patient with a histo-
ry of hypertension but without previous cardiac prob-
lems. He was admitted for an acute inferior wall
myocardial infarction 6 hours after the onset of chest
pain. Initial troponine T serum level was noted at 0.35
mg/l (N < 0.03 mg/l). On physical examination a loud
holosystolic murmur was heard at the lower left ster-
num border. Following this finding, initial echocar-
diography was performed and a muscular VSD with
a gradient of 55 mm Hg was described. Ejection frac-
tion (EF) was calculated at 60% with akinetic inferi-
or wall and right ventricle dilatation of up to 49 mm.
The day after this the patient was referred to our
institution for coronary angiography and VSD treat-
ment. The coronary angiogram demonstrated a nor-
mal left main artery, non-significant atherosclerot-
ic changes in the left anterior descending and very
distal left circumflex  80% stenosis. The dominant
right coronary artery was normal. The left ven-
triculography presented a VSD in the inferior sep-
tum with an estimated EF of 55% (Fig. 1). Cardiac
output was calculated at 3.19 l/min with a cardiac in-
dex of 1.92 l/min/m2. Qp/Qs was estimated at 1.67.
The VSD diameter was estimated to reach 13–14 mm
with a definite left-to-right shunt (Qp/Qs = 1.8) and
right ventricular dilatation.
After discussion with the patient and our car-
diac surgeons and in consideration of the respec-
tive interventional and surgical risks of VSD clo-
sure it was decided to proceed with percutaneous
closure.  Before the procedure the patient received
80 mg of Gentamycine IV and 2 g of Cefazoline IV
for endocarditis prophylaxis as well as 8000 U of
UFH. Then, general anesthesia was initiated with
Fentanyl IV and 8 F right femoral vein and 5 F right
femoral artery introducer sheaths were inserted.
A 5 F Pigtail 155° catheter was advanced into the
left ventricle. The VSD was measured before the
procedure with transesophageal echocardiography
(TEE) in the LAX view (VSD of 13–14 mm of dia-
meter) for AVSO device size selection. An Extra
Stiff 260 cm guidewire was inserted via the right
femoral artery across the aortic valve, the VSD and
the pulmonic valve, landing in the pulmonary artery.
This wire was exteriorised from the right intimal
jugular vein using a Microvena snare wire.
A 20 mm AVSO was inserted via the right jug-
ular vein and advanced in the VSD and deployed
under TEE guidance. Control left ventriculography
showed a successful deployment with only minimal
non-significant residual shunting (Fig. 2). This result
was also confirmed by TEE (Fig. 3). Subsequently left
and right ventricular pressures dropped from 110/0–20
to 99/0–20 mm Hg and from 50 mm Hg/19 mm Hg
to 34 mm Hg/13 mm Hg respectively. Cardiac out-
put and index rose to 7.9 l/min and 4.62 l/min/m2
respectively. Post-procedural and hospital follow-up
was uneventful. Six days later the patient was dis-
charged. Endocardial prophylaxis was maintained
for one year. Clopidogrel was prescribed for
6 months and acetylsalicylic acid indefinitely.
Figure 1. Left ventriculogram with ventricular septal de-
fect (arrow).
Figure 2. Amplatzer ventricular septal occluder in place.
No para-device leak. Transesophageal echocardiogra-
phy probe above.
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Discussion
Patients with post-AMI VSD may benefit from
a relatively quick and simple closure which may
allow hemodynamic stabilisation and survival. This
procedure can be performed as the definitive ther-
apy, as in the patient discussed here, or as a bridge
to future surgical correction in optimal conditions.
There are few reports on the efficacy of acute VSD
treatment. Thielle et al. [8] describe a series of
23 patients with acute VSD who were surgically
treated with prior insertion of an intra-aortic bal-
loon pump (IABP). The mean age of the patients
was 72 ± 10 years (ranging from 46 to 89) and the
interval from the onset of AMI to the detection of
VSD was 4 ± 4 days (ranging from 1 to 14). At the
time of enrolment 12 patients were in cardiogenic
shock (52%). The mean duration of IABP support
was 10.8 ± 9.5 days (ranging from 1 to 25) and
20 patients (87%) underwent surgical closure of the
VSD [8]. In the work of Thielle et al. [5] early sur-
gical closure because of cardiogenic shock result-
ed in an ominously high mortality rate of 83%. The
mortality rate in a hemodynamically stable group
with IABP with delayed surgery was at 29%.  Over-
all, perioperative mortality was 45%. Crenshaw
et al. [9], in the largest study of VSD, described
the outcomes of patients with VSD complicating
AMI in the GUSTO 1 trial. Mortality with this com-
plication remains extremely high despite improve-
ments in medical therapy. Patients who underwent
surgical repair had a lower mortality at 30 days and
one year then the patients who were treated med-
ically: 47% vs. 94% at 30 days (p < 0.001) and 53%
vs. 97% at 1 year (p < 0.001). Mortality rates for all
patients with VSDs were similar at 30 days and one
year (74% and 78%). These data suggest that if the
patient survives the initial treatment, the long-term
prognosis is relatively good [9]. Similarly, Landz-
berg and Lock [10] reported that, despite improve-
ments in the surgical management of ventricular
septal rupture after AMI, perioperative risk may be
excessive for some patients. They suggested that
optimal management of patients with post-MI ven-
tricular septal rupture requires surgical-medical col-
laboration and treatment selection based on individu-
al patients. In a registry in the USA, of 18 patients with
transcatheter closure of post-infarction VSD with an
Amplatzer muscular VSD occluder, the 28 day-mor-
tality was 28%. Five patients underwent the closure
in the acute phase within 6 days of infarct; the re-
maining patients underwent closure at any time from
14 to 95 days after diagnosis [11].
Conclusions
In the current American College of Cardiolo-
gy/American Heart Association guidelines urgent
surgery is recommended for acute ventricular sep-
tal defect regardless of hemodynamic status [12].
Despite an inherent high mortality risk, surgical
ventricular septal defect correction remains a life-
saving procedure that cannot be deferred [13, 14].
Acute ventricular septal defect closure with the
Amplatzer ventricular septal occluder may, however,
represent a viable alternative for these patients.
Nevertheless, long-term safety studies are required
before this technique becomes widely used in rou-
tine clinical practice. The obvious heterogeneity of
location and anatomy of ischemic ventricular sep-
tal defect calls for refinements in the technique and
occlusive devices.
Despite the very encouraging result of this in-
novative approach, further data, namely larger series
and long-term follow-up, need to be collected before
we may change our current treatment options.
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